The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients

Pathology and Oncology Research

Volumn 22, Issue 1, 2016, Pages 49-56

  Kucharczyk, Tomasz ^a,b   Krawczyk, Paweł ^a   Powrózek, Tomasz ^a   Kowalski, Dariusz M ^c   Ramlau, Rodryg ^d,e   Kalinka Warzocha, Ewa ^f   Knetki Wróblewska, Magdalena ^c   Winiarczyk, Kinga ^c   Krzakowski, Maciej ^c   Milanowski, Janusz ^a,g  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Wielkopolska Center of Pulmonology and Thoracosurgery of Eugenia and Janusz Zeyland   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f Regional Center of Oncology in Lodz   (Poland)

^g INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

MTHFR; Non small cell lung cancer; Pemetrexed monotherapy; Polymorphism; TS

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; DNA; PEMETREXED; THYMIDYLATE SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEREDITY; HETEROZYGOTE; HUMAN; INDEL MUTATION; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MTHFR GENE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TREATMENT OUTCOME; TS GENE; VARIABLE NUMBER OF TANDEM REPEAT; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM STAGING; PEMETREXED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 84951909006     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-015-9966-z     Document Type: Article

References (24)

1. Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551
3. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 22:1589–1597
4. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 31:2895–2902
5. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, et al. (2011) Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 74:132–138
6. Buque A, Aresti U, Calvo B, Sh Muhialdin J, Munoz A, Carerra S, et al. (2013) Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. PLoS One 8:e63338
7. Wang T, Chuan Pan C, Rui Yu J, Long Y, Hong Cai X, De Yin X, et al. (2013) Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: ameta-analysis. PLoS One 10(8):e74284
8. Ceppi P, Volante M, Saviozzi S, Rapa I, Nevello S, Cambieri A, et al. (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107:1589–1596
9. Tanaka F, Wada H, Fukui Y, Fukushima M (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 22:1791–1797
10. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, et al. (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78:92–99
11. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5’–terminal regulatory region for the human gene thymidylate synthase. Cell Struct Funct 20:191–197
12. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, et al. (2003) A novel single nucleotide polymorphism within the 5’ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898–2904
13. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, et al. (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319–327
14. Sulzyc-Bielicka V, Bielicki D, Binczak-Kuleta A, Kaczmarczyk M, Pioch W, Machoy-Mokrzynska M, et al. (2013) Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Gent Test Mol Biomarkers 17:799–780
15. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96:134–144
16. Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827–830
17. Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, et al. (2006) Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24:1603–1611
18. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113
19. Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, et al. (2012) Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02–2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol 30:4501–4507
20. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomized controlled trial. Lancet Oncol 13:247–255
21. Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, et al. (2010) The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 69:323–329
22. Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, et al. (2013) Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J 54:854–864
23. Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, et al. (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038–2045
24. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, et al. (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin. Lung Cancer 78:92–99